Valuation: PTC Therapeutics, Inc.

Market Cap 531.65Cr 471.94Cr 441.65Cr 400.31Cr 756Cr 51TCr 761.48Cr 5.3TCr 2.06TCr 26TCr 2TCr 1.95TCr 84TCr P/E 2026 *
41.3x
P/E 2027 * 24.9x
Enterprise Value 344.53Cr 305.84Cr 286.21Cr 259.42Cr 489.93Cr 33TCr 493.48Cr 3.44TCr 1.34TCr 17TCr 1.29TCr 1.27TCr 54TCr EV / Sales 2026 *
2.74x
EV / Sales 2027 * 2.3x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 531.65Cr
+1.26%-2.29%+36.97%+104.79% 1,03200Cr
+0.73%-4.78%+35.41%+61.62% 61TCr
+0.35%+1.29%+15.86%+79.90% 47TCr
+1.72%-4.92%+59.84%+36.64% 35TCr
+0.90%+1.12%+22.36%+40.72% 34TCr
+0.86%-1.60%+12.25%+33.94% 27TCr
-0.08%-2.79%-6.59%+9.97% 25TCr
-0.09%-4.97%+36.88%+50.52% 22TCr
-0.28%-4.66%+26.99%+92.98% 18TCr
Average +0.25%-3.39%+26.66%+56.79% 41.28TCr
Weighted average by Cap. +0.01%-3.18%+29.71%+67.12%

Financials

2026 *2027 *
Net sales 125.78Cr 111.66Cr 104.49Cr 95Cr 178.86Cr 12TCr 180.16Cr 1.25TCr 488.1Cr 6.19TCr 472.13Cr 462.01Cr 20TCr 137.69Cr 122.23Cr 114.38Cr 103.67Cr 195.8Cr 13TCr 197.21Cr 1.37TCr 534.32Cr 6.77TCr 516.83Cr 505.75Cr 22TCr
Net income 15Cr 13Cr 12Cr 11Cr 21Cr 1.4TCr 21Cr 145.08Cr 56Cr 715.06Cr 55Cr 53Cr 2.3TCr 22Cr 19Cr 18Cr 16Cr 31Cr 2.11TCr 31Cr 217.88Cr 85Cr 1.07TCr 82Cr 80Cr 3.45TCr
Net Debt -187.11Cr -166.1Cr -155.44Cr -140.89Cr -266.07Cr -18TCr -268Cr -1.87TCr -726.1Cr -9.2TCr -702.34Cr -687.28Cr -30TCr -214.54Cr -190.45Cr -178.22Cr -161.54Cr -305.08Cr -21TCr -307.28Cr -2.14TCr -832.54Cr -11TCr -805.29Cr -788.02Cr -34TCr
Projected Income Statement - Annual - PTC Therapeutics, Inc.
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - PTC Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
63.70USD
Average target price
101.79USD
Spread / Average Target
+59.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PTC Therapeutics, Inc.